Publicaciones en colaboración con investigadores/as de Charité (34)

2024

  1. Multivalent, calcium-independent binding of surfactant protein A and D to sulfated glycosaminoglycans of the alveolar epithelial glycocalyx

    American journal of physiology. Lung cellular and molecular physiology, Vol. 326, Núm. 5, pp. L524-L538

2023

  1. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1169-1203

  2. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs

    Nature Reviews Drug Discovery, Vol. 22, Núm. 9, pp. 743-767

2022

  1. Cigarette smoke augments CSF3 expression in neutrophils to compromise alveolar-capillary barrier function during influenza infection

    European Respiratory Journal, Vol. 60, Núm. 2

  2. EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 1, pp. 17-38

2021

  1. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy

    Clinical and Translational Allergy, Vol. 11, Núm. 4

  2. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 648-676

  3. Cysteine and iron accelerate the formation of ribose-5-phosphate, providing insights into the evolutionary origins of the metabolic network structure

    PLoS Biology, Vol. 19, Núm. 12

  4. EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 4, pp. 988-1009

  5. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 45-58

  6. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 59-70

  7. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  8. What is the contribution of IgE to nasal polyposis?

    Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 6, pp. 1997-2008

2020

  1. A compendium answering 150 questions on COVID-19 and SARS-CoV-2

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 10, pp. 2503-2541

  2. Air space distension precedes spontaneous fibrotic remodeling and impaired cholesterol metabolism in the absence of surfactant protein C

    American Journal of Respiratory Cell and Molecular Biology, Vol. 62, Núm. 4, pp. 466-478

  3. Allergic rhinitis

    Nature Reviews Disease Primers, Vol. 6, Núm. 1

  4. Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie

    Allergologie, Vol. 43, Núm. 7, pp. 255-271

  5. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 11, pp. 2764-2774

  6. In Vitro Functional and Structural Characterization of A Synthetic Clinical Pulmonary Surfactant with Enhanced Resistance to Inhibition

    Scientific Reports, Vol. 10, Núm. 1

  7. In-vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan—An EAACI position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 9, pp. 2161-2169